FIBROBIOLOGICS INC (FBLG) Stock Price & Overview
NASDAQ:FBLG • US31573L1052
Current stock price
The current stock price of FBLG is 1.42 USD. Today FBLG is down by -5.96%. In the past month the price decreased by -67.73%. In the past year, price decreased by -94.18%.
FBLG Key Statistics
- Market Cap
- 6.447M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -8.40
- Dividend Yield
- N/A
FBLG Stock Performance
FBLG Stock Chart
FBLG Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to FBLG. When comparing the yearly performance of all stocks, FBLG is a bad performer in the overall market: 99.38% of all stocks are doing better.
FBLG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FBLG. While FBLG seems to be doing ok healthwise, there are quite some concerns on its profitability.
FBLG Earnings
FBLG Forecast & Estimates
9 analysts have analysed FBLG and the average price target is 81.6 USD. This implies a price increase of 5646.48% is expected in the next year compared to the current price of 1.42.
FBLG Groups
Sector & Classification
FBLG Financial Highlights
Over the last trailing twelve months FBLG reported a non-GAAP Earnings per Share(EPS) of -8.4. The EPS decreased by -26.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -193.85% | ||
| ROE | -302.89% | ||
| Debt/Equity | 0 |
FBLG Ownership
FBLG Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 351.47B | ||
| AMGN | AMGEN INC | 15.09 | 185.95B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 161.855B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 109.449B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 79.456B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 40.768B | ||
| INSM | INSMED INC | N/A | 29.176B | ||
| NTRA | NATERA INC | N/A | 28.878B | ||
| BIIB | BIOGEN INC | 11.44 | 27.06B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.812B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 24.859B | ||
| MRNA | MODERNA INC | N/A | 20.119B | ||
| INCY | INCYTE CORP | 12.23 | 18.836B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FBLG
Company Profile
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 15 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Company Info
IPO: 2024-01-31
FIBROBIOLOGICS INC
455 E. Medical Center Blvd, Suite 300
Houston TEXAS US
Employees: 15
Phone: 12816715150
FIBROBIOLOGICS INC / FBLG FAQ
Can you describe the business of FIBROBIOLOGICS INC?
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 15 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
What is the stock price of FIBROBIOLOGICS INC today?
The current stock price of FBLG is 1.42 USD. The price decreased by -5.96% in the last trading session.
Does FIBROBIOLOGICS INC pay dividends?
FBLG does not pay a dividend.
What is the ChartMill rating of FIBROBIOLOGICS INC stock?
FBLG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does FIBROBIOLOGICS INC belong to?
FIBROBIOLOGICS INC (FBLG) operates in the Health Care sector and the Biotechnology industry.
What is the next earnings date for FBLG stock?
FIBROBIOLOGICS INC (FBLG) will report earnings on 2026-05-19.